Alkermes
Alkermes
ALKS
NASDAQ
34.73
USD
3.95%
About
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders.
It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.
ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.2M |
| Three Month Average Volume | 39.1M |
| High Low | |
| Fifty-Two Week High | 32.88 USD |
| Fifty-Two Week Low | 22.01 USD |
| Fifty-Two Week High Date | 16 Feb 2024 |
| Fifty-Two Week Low Date | 25 Oct 2023 |
| Price and Volume | |
| Current Price | 28.45 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -2.85% |
| Thirteen Week Relative Price Change | 13.60% |
| Twenty-Six Week Relative Price Change | -14.44% |
| Fifty-Two Week Relative Price Change | -22.22% |
| Year-to-Date Relative Price Change | -13.39% |
| Price Change | |
| One Day Price Change | 0.35% |
| Thirteen Week Price Change | 21.58% |
| Twenty-Six Week Price Change | -5.92% |
| Five Day Price Change | 1.79% |
| Fifty-Two Week Price Change | -2.54% |
| Year-to-Date Price Change | 2.56% |
| Month-to-Date Price Change | 4.14% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 7.20258 USD |
| Book Value Per Share (Most Recent Quarter) | 7.74025 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 6.69343 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 7.23422 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 2.52516 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 9.8003 USD |
| Revenue Per Share (Trailing Twelve Months) | 8.78306 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 3.05872 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 2.67285 USD |
| Normalized (Last Fiscal Year) | 3.08821 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 3.12326 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 2.7461 USD |
| Including Extraordinary Items (Last Fiscal Year) | 2.09602 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 1.68505 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.63224 USD |
| Cash Per Share (Most Recent Quarter) | 5.28142 USD |
| Cash Flow Per Share (Last Fiscal Year) | 3.42047 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 2.96741 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 1.90551 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 7 |
| Cash Flow Revenue (Trailing Twelve Months) | 22 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 26.08% |
| Pretax Margin (Last Fiscal Year) | 25.34% |
| Pretax Margin (5 Year) | 0.93% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 84.79% |
| Gross Margin (Trailing Twelve Months) | 83.31% |
| Gross Margin (5 Year) | 83.32% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 24.90% |
| Operating Margin (Trailing Twelve Months) | 24.91% |
| Operating Margin (5 Year) | 1.43% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 31.21% |
| Net Profit Margin (Trailing Twelve Months) | 30.34% |
| Net Profit Margin (5 Year) | 2.12% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -0.86% |
| Tangible Book Value (5 Year) | 4.72% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | 63.92% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -35.35% |
| Revenue Growth (3 Year) | 8.74% |
| Revenue Change (Trailing Twelve Months) | 3.14% |
| Revenue Per Share Growth | 6.80% |
| Revenue Growth (5 Year) | 16.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -7.10% |
| Total Debt (5 Year) | 0.80% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -65.97% |
| EPS Change (Trailing Twelve Months) | 52.40% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | 154.34% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 13 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 14 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -586,658,000 |
| Net Debt (Last Fiscal Year) | -482,761,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 3 |
| Price to Sales (Trailing Twelve Months) | 3 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 11 |
| PE Normalized (Last Fiscal Year) | 9 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 9 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 18 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 7 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 17 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 4 |
| Price to Book (Most Recent Quarter) | 4 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 24 |
| Long Term Debt to Equity (Most Recent Quarter) | 22 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 0.00% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 2 |
| Quick Ratio (Most Recent Quarter) | 3 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 8 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 9 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 353.3M |
| Free Cash Flow (Trailing Twelve Months) | 327.1M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 24 |
| Total Debt to Equity (Most Recent Quarter) | 23 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 25.32% |
| Return on Assets (Trailing Twelve Months) | 20.83% |
| Return on Assets (5 Year) | 1.34% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 46.22% |
| Return on Equity (Trailing Twelve Months) | 35.68% |
| Return on Equity (5 Year) | 2.37% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 33.69% |
| Return on Investment (Trailing Twelve Months) | 26.98% |
| Return on Investment (5 Year) | 1.74% |